Compare CBC & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBC | ERAS |
|---|---|---|
| Founded | 1902 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7B | 6.3B |
| IPO Year | 2025 | 2021 |
| Metric | CBC | ERAS |
|---|---|---|
| Price | $32.26 | $15.53 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $34.60 | $24.11 |
| AVG Volume (30 Days) | 1.2M | ★ 4.4M |
| Earning Date | 10-27-2026 | 11-11-2026 |
| Dividend Yield | ★ 1.51% | N/A |
| EPS Growth | 25.90 | ★ 36.23 |
| EPS | ★ 0.94 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.45 | N/A |
| Revenue Next Year | $5.25 | N/A |
| P/E Ratio | $33.89 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.50 | $2.11 |
| 52 Week High | $33.82 | $24.28 |
| Indicator | CBC | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 54.49 | 49.51 |
| Support Level | $31.93 | $13.48 |
| Resistance Level | $32.36 | $16.14 |
| Average True Range (ATR) | 0.65 | 0.95 |
| MACD | 0.06 | 0.11 |
| Stochastic Oscillator | 93.21 | 80.58 |
Central Bancompany Inc is a bank holding company that provides a broad range of retail, corporate, mortgage banking, wealth management, and trust products and services to individuals and businesses. Its operating segments include Consumer, Commercial, and Wealth Management. The company generates the majority of its revenue from the Commercial segment, which provides full-service relationship banking solutions to businesses, agencies, and community organizations, including commercial, small business, and government clients. The segment also offers business payment solutions such as treasury management services, merchant services, and commercial bank card products.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.